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1. Introduction 
At the cellular level, cancers originate from the monoclonal expansion of a mutant cell 
leading to accumulation of aberrant cells that continue to lose differentiated features and 
acquire different biological properties in their progression toward disseminated or 
metastatic disease. The onset and progression of cancer involves genomic derangements that 
can be manifested in two ways: 1) Genetic and gross structural defects (e.g. single nucleotide 
polymorphism (SNP), classic deletion, insertion mutation, chromosomal 
deletion/inversion/translocation, allelic loss/gain, gene amplification/ deletion), and 2) 
Aberrant epigenetic covalent modifications (e.g. DNA methylation, histone acetylation, 
methylation, phosphorylation, citrullination, sumolyation, and ADP ribosylation). 
Genomic instability can be triggered by chemical carcinogens, radiation, stress, oncogenic 
DNA viruses and the aging process. In almost all cancers, genomic instability in the form of 
genetic alterations or epigenetic modifications affects four classes of genes: oncogenes, 
tumor suppressor genes, apoptotic genes and/or DNA repair genes. Oncogenes encode 
proteins that function as positive proliferative signals for tumors. Tumor suppressor genes 
negatively regulate cell proliferation and are inactivated in many tumors. Apoptotic genes 
encode proteins that instruct the cell to commit suicide, while DNA repair genes encode 
proteins that maintain the fidelity of DNA sequences during transcription and replication. 
The uncontrolled expression of oncogenes or the silencing of tumor suppressor genes can 
lead to immortalization of cells. For example, in neuroblastoma, the overexpresssion of N-
myc oncogene correlates with aggressive tumor behavior (Seeger et al., 1985). The ras 
oncogene is activated in more than half of the tumors studied in humans (Barbacid et al., 
1987), and both relapse and decreased survival in breast cancer patients have been 
associated with overexpression of Her-2 oncogene (Slamon et al., 1987). The tumor 
suppressor and cell cycle regulator gene, p53, is mutated or deleted in more than 50% of 
human tumors (Hollstein M et al., 1991). p53 gene is described as the guardian of the 
genome because it can activate DNA repair genes when DNA is damaged, or induce 
apoptosis when DNA damage is sensed to be irreparable.  
Despite the presence of defective genes in tumors, tumors actually arise through many 
different combinations of genetic alterations. The phenotypic diversity observed between 
normal and cancer cells cannot be explained simply by structural and genetic alterations. 
Epigenetic mechanisms have been shown to activate or inactivate genes. Conrad 
Waddington first coined the term epigenetic to mean changes above and beyond (epi) the 
primary DNA sequence (Waddington, 1939). The term epigenetic refers to heritable genetic 
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variations that give rise to distinct patterns of terminal differentiation phenotypes 
(Waddington, 1952; Ruden et al., 2005; Goldberg et al., 2007). These heritable variations are 
independent of the DNA sequence, can be reversible, and often are self-perpetuating 
(Bonasia et al 2010). Epigenetic modifications can include DNA methylation, histone 
acetylation, histone methylation, histone phosphorylation, citrullination, sumoylation, and 
ADP ribosylation. A classic example of epigenetic control is seen as cells undergo 
differentiation during development (Figure 1). While every cell in the human body has 
identical DNA sequence (except for T and B cells), epigenetic patterns lead the same cells to 
differentiate into a wide array of cell types and the formation of different tissues or organs 
(Figure 1). Also, animals cloned from the same donor DNA are not identical and develop 
diseases with different penetrance from the donor parent (Esteller, 2008; Rideout 3rd et al., 
2001). The methylation patterns (Fraga et al., 2005b; Kaminsky et al., 2009), and histone 
modification profiles (Kaminsky et al., 2009), are different in monozygote twins, indicating 
that while epigenetic patterns are stable and heritable, they are also dynamic in the sense 
that genes can be silenced or activated due to changes in cellular environment (Figure 1). In 
normal cells, epigenetic patterns are in dynamic equilibrium (Szyf, 2007). Many diseases, of 
which cancer is no exception, arise when different types of epigenetic patterns are 
introduced at the wrong time, and/or the wrong place. For example, the hypermethylation 
of tumor suppressor genes, t16INK4a, p14ARF and MGMT, has been reported as an early event  
 
 
Fig. 1. Epigenetic changes leading to activation or silencing of genes during development. 
Depicted in the figure is the time dependent activation or inactivation of key genes during 
development (i.e. from zygote to specialized cells). While every cell has exactly the same DNA 
composition, the interplay between epigenetic modifications such as DNA methylation or 
histone modifications (e.g. histone methylation, acetylation, phosphorylation, ubiquitination 
and sumoylation) can lead to the expression or silencing of pluriponent genes, lineage specific 
genes or tissue specific genes during development leading to the formation of specialized cells 
or organs. Peaks depict activation and troughs denote silencing. 
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in tumorigenesis (Esteller et a., 2007). Because such epigenetic changes are reversible, the 
epigenome of cancer cells represents an ideal target for cancer treatments. Tumor 
suppressor genes turned off can be switch back on, and oncogenes turned on can be 
switched off to restore the epigenetic balance of cancer cells. How epigenetic modifications 
occur, and how epigenetic profiles define the genomic landscape of cancerous cells and their 
response to treatment will be the focus of this chapter.  
2. Fundamentals of epigenetics 
Epigenetic modifications can broadly be classified into three categories: DNA methylation, 
histone modification and nucleosome positioning. Epigenetic phenotypes result from the 
interplay between these three categories. Within the microenvironment of the cell, 
epigenetic patterns are established by transiently activated, and/or stably expressed factors 
that respond to environmental stimuli, developmental cues, or internal events. Of particular 
importance within the context of cancer, is the impact of exogenous substances on 
epigenetic modifications of gene regulation. Since the treatment of many cancers involves 
exposure to toxic substances, it is important to understand how some of these substances 
regulate epigenetic modifications. Hence the trajectory of cancer treatment is leaning toward 
a treatment regimen that includes epigenetic drugs capable of modifying the neoplastic 
phenotypes to induce shifts in phenotypic expression rather than cytotoxic alterations. 
2.1 DNA methylation 
DNA methylation was the first identified epigenetic regulation of gene expression in 
mammals (Holliday and Pugh, 1975; Riggs, 1975). It occurs by enzymatic transfer of a 
methyl group to carbon 5 of the pyrimidine base, cytosine, in the 5’-3’ cytosine guanine 
(CpG) dinucleotide sequence. Mainly, S-adenosylmethionine (SAM) acts as methyl donor in 
this reaction. DNA methylation can be classified into four categories based on the region of 
the genome where methylation occurs. The first identified DNA methylation occurs 
exclusively in CpG dinucleotides. CpG dinucleotides normally cluster in regions of DNA 
called CpG islands. They are regions of DNA approximately 200-500 bases long with a G + 
C content  greater than 50% and CpG to GC ratio of at least 0.6 (Bird, 1986; Gardiner-Garden 
and Frommer, 1987). CpG dinucleotides constitute 1% of the genome and are normally 
found in the promoter region of genes (Figures 2a and 2b). For example, the promoters of 
50-70% of known human genes contain CpG dinucleotides (Bird et al., 1987; Larson et al., 
1982; Wang and Lung, 2004). The second kind of DNA methylation is called gene body 
methylation (Hellman and Chess, 2007). This type of methylation occurs in the open reading 
frame of genes (Figure 2b) and functions to prevent spurious transcriptional initiation 
(Hellman and Chess, 2007), or alternative splicing of mainly ubiquitously expressed genes 
(Zilberman et al., 2007). Recently it has been suggested that gene body methylation also 
occurs at non CpG dinucleotides (i.e. CHG or CHH sites where H =A, C or T) (Lister et al., 
2009; Laurent et al., 2010). A third kind of DNA methylation occurs at CpG island shores 
(Irizarry et al., 2009; Doi et al., 2009). The term CpG island shores refers to regions of the 
genome with lower density of CpG dinucleotides that lay approximately 2000 bases away 
from the CpG islands (Figure 2d). The CpG island shores determines the methylation 
pattern of tissues (Irizarry et al., 2009; Doi et al., 2009), and the reprogramming of stem cells 
(Doi et al., 2009; Ji et al., 2010). A fourth kind of DNA methylation occurs at repetitive 
sequences (e.g. transposable elements and microsatellite regions) (Figure 2e and 2f). The 
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transposable sequences constitute about 47% of the entire genome (Babushok and Kazazian, 
2007). Examples of transposable elements are the DNA transposons (e.g. Mer1/2) and 
retrotransposons (e.g. non-terminal repeat retrotransposon, such as Lines and Sines and 
long terminal repeat retrotransposon, such as HERVs and IAPs). When activated, these 
repetitive sequences can move from one region of the genome to another through a so called 
“cut and paste” or “copy and paste” mechanisms, respectively. Microsatellites are tandem 
repeats of DNA embedded in various regions of the genome, and their methylation can 
result in either gene silencing or chromosome instability if it occurs in centromeric regions 
of the chromosome.  
All four types of DNA methylation are catalyzed by a class of enzymes called DNA 
methyltransferases (DNMT). In mammals, there are five DNMT isoforms: DNMT1, DNMT2, 
DNMT3a, DNMT3b and DNMT3L (Siedlecki and Zielenkiewicz, 2006). The catalytic domain 
is conserved between the DNMTs (except DNMT3L), while the regulatory domain 
responsible for a protein-protein interaction is variable. DNMT1 is a maintenance 
methyltransferase that ensures the pattern of DNA methylation is transferred from daughter 
to parent. DNMT1 and proliferating cell nuclear antigen (PCNA) colocalize to DNA 
replication foci in early S phase (Chuang et al., 1997). Loss of DNMT1 causes cell cycle arrest 
and apoptosis (Chen et al., 2007). DNMT2 has little DNA methylation activity and DNMT2 
knockout mice display no aberrant DNA methylation patterns (Okano et al., 1998). Studies 
by Goll et al. (2006) have shown that the main function of DNMT2 is to methylate tRNA 
outside the nucleus. DNMT3a and DNMT3b are de novo methyltransferases responsible for 
establishing methylation patterns during early development. These de novo DNMTs are 
highly expressed in embryonic stem cells and their expression is downregulated after 
differentiation (Esteller et al., 2007). DNMT3L lacks the catalytic domain and is involved in 
establishing maternal genomic imprinting by acting as a stimulatory factor for DNMT3a and 
DNMT3b (Bourc’his et al., 2001). DNMT3L has been shown to interact and colocalize with 
both DNMT3a and DNMT3b in the nucleus (Chen et al 2005; Holt-Schietinger et al., 2010).  
In general, DNA methylations (except gene body methylation) inhibit gene expression. 
DNA methylation at CpG islands, CpG island shores and repetitive sequence alters the 
conformation of the DNA in such a way that it prevents recruitment of transcription factors 
and positive regulators. In addition, methylated DNA promotes the recruitment of Methyl–
CpG binding (MBD) proteins (Lopez-Serra and Esteller, 2008). Five classes of MBDs have 
been identified: MeCP2, MBD1, MBD2, MBD3, and MBD4. MBDs recruit histone 
deacetylases (HDACs) and histone methyltransferase (HMTs). HMTs methylate histone, 
with methylated histones being recognized and bound by heterochromatin complexes, such 
as heterochromatin protein 1 (HP1). These conditions combine to create a chromatin 
structure (heterochromatin) that favors transcriptional repression. Conversely, 
unmethylated DNA favors the formation of active chromatin (euchromatin). The formation 
of active chromatin results in recruitment of histone acetyltansferases and methyltrasferases 
which create domains characterized by high levels of acetylation and trimethylation at 
H3K4, H3K36 and H3K79 leading to unwinding of chromatin and binding of transcriptional 
factors that lead to gene expression.  
Compared to normal cells, cancer cells are characterized by global hypomethylation (overall 
20-60 less CpG methylation) (Goel et al., 1985). Hypomethylation in cancer cells results in 
the induction of oncogenic genes, loss of imprinting, activation of transposable elements and 
microsatellite instability (Dunn, 2003; Esteller, 2008) (Figure 2). Hypomethylation at specific 
promoters can lead to aberrant expression of oncogenes and loss of imprinting (Figure 2a).  
www.intechopen.com
 Epigenetic Therapies for Cancer 
 
545 
 
Fig. 2. Methylation patterns in normal versus cancer cells. A. Hypomethylation of oncogene 
leads to their activation in cancer cells. B. Hypermethylation at the promoter region of a 
tumor suppressor gene leads to their silencing in cancer cells. C. Gene body 
hypomethylation leads to spurious transcription initiation in ubiquitously expressed genes. 
D. Hypomethylation at CpG island shores leads to ubiquitous expression of key regulatory 
genes. E & F. Hypomethylation at repetitive or microsatellite sequences leads to expression 
of transoposable elements and chromosomal instability, respectively. 
Oncogenes such as S100P, SNCG, melanoma-associated gene (MAGE) and dipeptidyl 
peptidase 6 (DPP6) are hypomethylated in pancreatic cancer, breast cancer and melanomas, 
respectively (Wilson et al., 2007; Irizarry et al., 2009). This hypomethylation converts the 
expression of these genes into aberrantly expressed genes leading to increase growth and 
metastatic advantage. Loss of imprinting due to hypomethylation has been reported for 
insulin–like growth factor 2 (IGF2) gene in breast, liver, lung and colon cancers (Ito et al., 
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2008). Repetitive sequences are hypomethylated and reactivated in many cancers (Goel et 
al., 1985; Gaudet et al., 2003; Futscher et al., 2004), as documented for lung, breast, bladder, 
and liver cancers (Wilson et al., 2007). Lastly, hypomethylation of microsatellite regions at 
the pericentromeric region leads to genomic instability (Kuismanen et al., 1999). 
While the genomes of cancer cells are globally hypomethylated, some aberrant DNA 
methylation occurs at specific regions of the genome (Figure 2b). These aberrant 
methylations affect the expression of genes involved in cell cycle control (e.g. p53, Rb, 
p16INK4a, p15INK4b), apoptosis (TMSI, DAPKI, WIF-1 and SERP1) and DNA repair (e.g. 
BRAC1, WRN, MGMT, hMLH1). For example, hypermethylation of the CpG dinucleotide in 
the promoter region of the tumor suppressor gene p16 occurs in 20% of human cancers 
(Merlo et al., 1995). In addition, the guardian of the genome, p53, is epigenetically silenced 
in a large proportion of human cancers (Hollstein et al 1991; Jirtle, 1999, Jirtle and Skinner 
2007; Jones and Baylin, 2004). Hypermethylation of the promoter region of MASPIN gene 
was reported as an early event in breast cancer (Futcher et al., 2004). Hypermethylation at 
CpG regions is also prone to spontaneous point mutations. Methylated cytosines can 
undergo spontaneous deamination and a subsequent conversion to uracil leading to C-T 
transition. This results in a rate of mutation at methylated CpG regions that is 42 times 
higher than predicted for random mutation (Cooper and Youssoufian, 1998). Point mutation 
(C-T) is frequently seen in p53 and Rb genes leading to loss of function of these proteins 
(Cooper and Youssoufian, 1988; Magewu and Jone, 1994; Tornaletti and Pfeifer, 1995; Manici 
et al., 1997). In addition, CpG sites are favored binding sites for carcinogens which also lead 
to increase rates of CpG mutations (Magewu and Jone, 1994; Yoon et al., 2001). 
The question of why some regions of the genome are hypermethylated and others 
hypomethylated in cancer is poorly understood. However, most of the hypomethylated 
regions in tumors lie outside the so called CpG islands. In normal cells, these non CpG 
regions are methylated. Also the patterns of hypermethylation are tumor-specific leading to 
the idea that selection pressures in favor of growth for clonal cells might lead to different 
patterns of methylation. Another explanation for the site-specific hypermethylation could be 
due to recruitment of DNMTs by accessory proteins in cancer cells. The identity of these 
accessory proteins may be unique to the cancer cell phenotype, and also exhibit specificity 
for different cancer subtypes. Finally, epigenetic profiles in cancer may involve 
dysregulation of DNMT expression. This suggestion is consistent with the finding that 
DNMT1 and DNMT3b are overexpressed in many tumors (Miremadi et al., 2007). In 
addition, many tumors are characterized by downregulation of miRNAs due to methylation 
at their promoters (Saito et al., 2006; Melo et al., 2009). Conversely, miRNAs have also been 
shown to target DNMTs. In fact, miR-29 has been shown to target and downregulate both 
DNMT3a and DNMT3b, and indirectly DNMT3L (Garzon et al., 2009). Compared to normal 
cells, it is possible that regulation of DNMTs by miRNAs is dysregulated in cancer cells 
resulting in unique patterns of DNMT expression. 
2.2 Nucleasome positioning 
Total eukaryotic DNA is 2m long and must fit into the nucleus which has an approximate 
size of 2µm3. This is accomplished by an elaborate interaction between DNA, four core 
histone proteins (i.e. H2A, H2B, H3 and H4) and one linker histone. The core histone 
proteins are arranged into two sets of H3/H4 and H2A/H2B heterodimers. This 
arrangement forms into an octomer shaped structure, called the nucleosome, around which 
~146bp of DNA is wrapped (Kornberg 1974). The interaction between the nucleosome and 
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DNA is facilitated by the positively charged amino acids of the histone proteins and the 
negatively charged phosphate backbone of the DNA. Nucleosomes are separated from each 
other by 20-100 bp linker regions. The linker region is bound by another histone protein 
called histone 1 (H1). H1 and its variants function to promote the coiling of nucleosomes 
into fiber like structures in cells (Bedner et al., 1998). Linker histones are distinguished from 
other histones because of special modifications at key amino acids, or in their tail regions or 
domain structures (Li et al., 2007). Nucleosomes, DNA and linker histones are packaged to 
form chromatin. The conformation of chromatin is determined by the positioning of the 
nucleosome and its level of modification. For example, loss of nucleosomes at the 
transcription start site is directly correlated to gene expression (Figure 3), and occlusion of 
the nucleosome at transcription start sites is correlated with transcriptional repression 
(Schomes et al., 2008; Cairns et al., 2009). At this level, nucleosomes act as barriers to 
transcription because they block access to binding sites for transcription factors and 
regulators (Figure 3), or block elongation by sterically hindering the movement of RNA 
polymerase II. The precise position of the nucleosome is influenced by linker histones 
(Zilberman et al., 2007), and chromatin remodeling complexes (Clapier et al., 2009). 
Incorporation of different histone variants can influence transcription and the methylation 
landscape in eukaryotic cells (Chodavarapu et al., 2010). For example, incorporation of 
histone linker H2A.Z protects genes against DNA methylation (Zilberman et al., 2008), 
thereby playing a role in epigenetic activation of transcription.  
The chromatin remodeling complexes are classified into four families: mating type 
switch/sucrose non-fermenting (SWI/SNF) family, chromodomain helicase DNA-binding 
(CHD) family, Imitation SWItch (ISWI) family and Inositol/choline responsive element 
dependent gene activation mutant-80 (INO80) family. These four families are distinguished 
by unique features within their catalytic subunits that allow them to read specific histone 
post-translational modifications that stabilize their interaction with chromatin. They also 
differ in the composition of the other subunits (Ho and Crabtree, 2010). Chromatin 
remodeling complexes function by moving, ejecting, destabilizing or restructuring the 
nucleosome in an ATP dependent manner. The remodeling machinery is also influenced by 
both DNA methylation (Harikrisnan et al., 2005), and histone modifications (Wysoca et al., 
2006).  
Mammalian SWI/SNF enzymes are multisubunit complexes of 1–2MDa and consist of 9–12 
subunits, one of which is an ATPase (De la Serna et al., 2006). The ATPase subunit is 
identified as either Brahma (BRM) or brama/swi2-related gene-1(BRGI) which have been 
recognized as human homologs. The BRGI subunit is 75% identical between SWI/SNF 
family members. Functionally, SWI/SNFs are master regulators of gene expression. For 
example, SWI/SNFs are involved in regulating the expression of FOS, CRYAB, MIM-1, p21 
and CSF-1. These complexes are also involved in alternative splicing (Reisman et al., 2009).  
The CHD family of chromatin remodeling complexes is distinguished by having two 
chromodomains that have affinity for methylated histones (Marfella et al., 2007). There are 
nine CHD proteins that can be divided into three subfamilies based on the presence of other 
conserved domains and interacting factors: I. (CHD1 and 2), II. (CHD3 and 4), III. (CHD 5–
9). Some CHD family members are involved in the sliding and ejection of the nucleosome 
thereby promoting transcriptional activation. Others like Mi-2/NuRD have HDAC activity 
and can also act as methyl binding protein (Clapier et al., 2009). These family members at 
this role act as transcriptional repressors.  
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Fig. 3. Chromatin exists in a transcriptionally repressed (heterochromatin) or 
transcriptionally active (Euchromatin) states. Epigenetic modifications such as DNA 
methylation, histone methylation, phosphorylation, sumoylation and ubiquination favor the 
formation of heterochromatin and lead to transcriptional repression. Conversely, histone 
acetylation, methylation, phosphorylation and ubiquitination favor the formation of 
euchromatin and transcriptional activation. Note that epigenetic modifications, such as 
histone methylation, phosphorylation and ubiquitination, favor both the formation of 
euchromatin and heterochromatin. This depends on the composition of trans-acting factors, 
cross talk between histone marks, microdomain created by the histone marks and the 
chromatin remodeling complexes. Additional details can be found in the text. HMT: Histone 
methyltranferase, HAT: Histone acetyltransferase; DNMT: DNA methyltransferase; E3: E3 
ubiquitin ligase: E3 Sumo: E3 sumo ligase; HP1: heterochromatin protein 1; TF: transcription 
factor; Pol: Polymerase; Ac: Acetylation mark; CH3: Methylation mark. 
Imitation SWItch (ISWI) complexes were initially identified and purified from Drosophila 
embryo extracts as NUcleosome Remodeling Factor (NURF), ATP dependent Chromatin 
assembly and remodeling Factor (ACF), and CHRomatin Accessibility Complex (CHRAC) 
complexes. Currently ISWI complexes have been found in a variety of organisms from yeast 
to humans (Tsukiyama and Wu, 1995; Tsukiyama et al., 1995; Ito et al., 1997; Varga-Weisz et 
al., 1997). The ISWI family members such as ACT and CHRAC are involved in promoting 
chromatin assembly, thus acting as transcriptional repressors. However, the NURF complex 
has been shown to activate RNA polymerase II, thus acting as a transcriptional activator. 
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INO80 was identified as a gene encoding an ATPase that is incorporated into a large 
multisubunit complex (Ebbert et al., 1999). Biochemical characterization of the yeast INO80 
complex has revealed the presence of chromatin remodeling activity and 3’-5’ helicase 
activity (Shen et al., 2000). Yeast cells that lack either INO80 or one of its core subunits (Arp5 
andArp8) exhibit hypersensitivity to DNA damaging agents, suggesting that the INO80 
complex is involved in DNA repair (Morrison et al., 2004; van Attikum et al., 2004). In 
accord with these findings, the INO80 complex is recruited to sites of double strand DNA 
breaks through interaction with phosphorylated H2A. From these findings and others, 
members of the INO80 family are believed to be involved in DNA repair, chromosomal 
segregation, DNA replication, telomere regulation and transcriptional activation (Ho et al., 
2010). However, SWRI functions to restructure the nucleosome by removing the H2A-H2B 
dimers and replacing them with H2A.Z-H2B dimers (Clapier et al., 2009). 
All four families of chromatin remodeling complexes are believed to be involved in 
tumorigenesis. For example, the BRGI subunit of the SWI/SNF families has been 
characterized as a tumor suppressor, and is silenced in about 20% of non-small lung cancer 
(Medina et al., 2008). BRGI subunit also functions to destabilize p53 hence acting as a tumor 
suppressor (Naidu et al., 2009). SWI/SNF complexes have been shown to interact with 
oncogenes, such as Rb, Myc, p53, breast cancer 1(BRCA1) and myeloid/lymphoid or mixed–
lineage leukemia (MLL) (Roberts et al., 2004). Point mutations in the SNF subunit of the 
SWI/SNF complex have been implicated in renal tumors, choroid plexus carcinomas, 
meduloblastoma and neurorectodermal tumors (Robert et al., 2004). In colon cancer, 
promoter hypermethylation of the MLH1 gene results in occlusion of the transcription start 
site by nucleosomes (Lin et al., 2007). The CHD5 complexes are targets of CpG 
hypermethylation (Mulero-Navarro and Esteller, 2008) resulting in downregulation of these 
complexes. In addition, crosstalk between chromatin remodeling complexes and histone 
modifications is vital to transcription regulation and tumorigenesis. For example, members 
of the CHD family are components of the NRD deacetylating and the SAGA 
acetyltransferase complexes (Tong et al., 1998). In accord with these findings, The H3K4 
methyltransferase MLL has been shown to interact with SNF5/BRG1-associated factors 
(BAF) 47 (Rozenblatt-Rosen et al., 1998), and H3K4 methylation has been shown to recruit 
and mediate association of ISWI with chromatin to initiate transcription (Santos-Rosa et al., 
2003). Acetylation of H3K56 leads to recruitment of SWI/SNF complexes (Xu et al., 2005). 
Linker histones have also been shown to play a role in tumorigenesis, with increased 
expression of linker histone macroH2A in senescent lung cells (Sporn et al., 2009), indicating 
that lung tumors with high expression of macroH2A have a better prognosis. 
2.3 Histone modifications 
As noted, chromatin is made of DNA and its associated proteins which are in turn classified 
into histone and non-histone proteins. Non-histone proteins transiently interact with the 
DNA to regulate function after which they dropout or are removed. For example, non-
histone proteins transiently interact with DNA during transcription, replication, and DNA 
repair mechanisms. Such proteins include polymerases, co-activators, co-repressors, 
chromatin remodeling complexes, structural proteins and histone like proteins (e.g. CENPS). 
On the other hand, histone proteins stably interact with DNA except during transcription, 
replication or DNA repair during which they are temporally displaced from the DNA as 
nucleosomes. Each histone can be divided into three segments: a basic N-terminal histone 
tail, a globular histone fold and a C-terminal tail. The conformation of chromatin is 
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dependent on posttranslational modifications at the tails of all histones which normally 
protrude from the nucleosome. Posttranslational modifications function by contouring the 
secondary structures of chromatin so as to allow or disallow accessibility to transcription 
and regulation sites. Posttranslational modification on histone can be classified as transient 
or stable. Transient posttranslational modifications include:  phosphorylation, sumoylation 
and ubiquitination, and represent modifications that correlate with transient changes in 
gene regulation. Acetylation and methylation are fairly stable modifications that reflect the 
conformation of chromatin (e.g. closed/heterochromatin and open/euchromatin).  
2.3.1 Histone acetylation 
All histones are subjected to acetylation, and the process is catalyzed by histone 
acetyltransferase (HAT) complexes (Allfrey et al., 1964). Histone acetylation involves the 
transfer of acetyl groups from acetyl Coenzyme A to the imino group of lysine. HATs do not 
acetylate lysine moieties on histone randomly, a potential recognition motif (GKxxP) was 
revealed by crystal structure analysis (Rojas et al., 1999; Bannister et al., 2000). However, this 
motif is not a predictor of non-histone protein acetylation as a proteomic survey has 
identified different sets of preferentially acetylated amino acid stretches (Kim et al., 2006). 
Functionally, histone acetylation induces the so called open/euchromatin conformation via 
steric hinderance, changes in the positive charges of histones (Hong et al., 1993), and/or 
recruitment of regulatory proteins (Grant and Berger, 1999; Roth et al., 2001). The formation 
of open chromatin favors transcriptional activation. At the same time, the acetyl group of 
histones can be removed by histone deacetylase complexes (HDACs) which favors 
formation of closed chromatin and transcriptional repression (Yang and Seto, 2003). HATs 
are categorized into two groups based on their cellular localization. Type-A HATs are 
nuclear and acetylate histones and other chromatin-associated proteins. Type-B HATs are 
localized in the cytoplasm and have no direct influence on transcription. The latter are 
believed to function mainly to acetylate newly synthesized histones in the cytoplasm. Type-
A HAT are further categorized into three groups: GNAT [GCN5 (general control of nuclear-
5)-related N-acetyltransferase], p300/CBP [CREB (cAMP response element binding protein)-
binding protein] and MYST [MOZ (Monocytic leukaemia zinc-finger protein), YBF2 (Yeast 
binding factor2)/SAS (something silencing), Tip60 (Tat interactive protein -60)] (Table 1). In 
addition some transcription factors and nuclear receptor coactivators have been shown to 
acetylate histones. For example, the nuclear receptor coactivator, Amplified in breast cancer-
1 (AIB1), and transcription factor, TATA-box binding protein associated factor-250 
(TAF250). Both of these proteins have been shown to acetylate histones H3 and H4.  
The mechanism by which HAT complexes are recruited to the chromatin to acetylate 
histones is poorly understood. One possible mechanism involves the recruitment of HAT 
proteins as part of coactivator complexes. For example, p300/CBP HAT complexes are 
found to associate with polymerase II during transcription (Nakajima et al., 1997). Another 
plausible mechanism is through association with bromodomains containing proteins which 
recognize and bind to acetylated lysines (Dhalluim et al., 1999; Mujtaba et al., 2002). For 
example, the SWI/SNF complexes are recruited to the chromatin via their bromodomains 
(Hassan et al., 2002). In this case the HAT families of proteins are believed to complex with 
SWI/SNF complexes to acetylate histones. 
The primary site for histone acetylation is the tail region which generally protrudes from the 
nucleosome. For example, core histones H3 and H4 can be acetylated at lysines 9, 14, 18, 23 
and 5, 8, 12, 16 respectively (Roth et al., 2001) (Table 1). Histone acetylation can occur at 
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different sites giving rise to the possibility of functional crosstalk between different 
acetylation marks. In fact, communication is known to occur between the same histone 
marks (Wang et al., 2008), between marks within the same histone tail (Duan et al., 2008), or 
between marks in different histone tails (Nakanishi et al., 2008). These data suggest that a 
single acetylation mark does not determine the state of the chromatin. Indeed, the notion of 
a strictly closed and open chromatin conformation has been challenged by a recent study 
showing that up to 51 chromatin states are possible based on the level or combination of 
acetylation marks (Ernst et al., 2010). For example, an active H3K4me mark and a repressive 
H3K27me mark have been found to co-exist in embryonic stem cells, suggesting a chromatin 
state that is neither open nor closed (Bernstein et al., 2006; Mikkelsen  et al., 2007). 
 
 
Table 1. HATs families and substrate specifications 
As noted earlier, acetylation is a reversible process and the removal of acetyl groups is 
catalyzed by a class of enzymes called histone deacetylases (HDACs). Histone deacetylation 
is correlated with transcriptional repression. In humans, 18 isoenzymes of HDACs have 
been identified to date, and grouped into four classes based on their homology to yeast 
HDACs (Table 2). Class I (HDAC1, 2, 3 and 8) are related to yeast RPD3 gene and are mostly 
located in the nuclei, except HDACs 3 and 8 which can also be cytoplasmic. Class II (HDAC 
4, 5, 6, 7, 9 and 10) are related to yeast Hda1 gene and are primarily located in the cytoplasm, 
but can shuttle to nucleus. Class II HDACs are further divided into two subclasses, IIa 
(HDAC 4, 5, 7,9) and IIb (HDAC 6, 10), based on their sequence homology and domain 
organization. Class III, also known as the sirtuins (SIRTIUNS (SIRT) 1–7), are related to the 
yeast Sir2 gene, and are virtually unaffected by class I and II HDAC inhibitors. They are 
localized in the cytoplasm, mitochondria and nucleus (Table 2). Class IV (HDAC11) has a 
conserved domain similar to the catalytic region of Class I HDACs. Class IV is a fairly new 
class and needs further characterization. Classess I, II and IV share similar structural 
organization and a common cofactor, Zn2+. Class III HDACs are structurally different from 
the rest and their active site is occupied by the nicotinamide adenine dinucleotide (NAD). 
Functionally, class II HDACs are regulated by class I HDACs and together class I and II are 
involved in transcriptional silencing and genomic organization during development. Class 
III HDACs are involved in maintenance of acetylation, as well as specific gene silencing 
(Denu et al., 2003). 
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NAD: Nicotinamide adenine dinucleotide; SIRT: Sirtiun; Zn: Zinc 
Table 2. Classes of HDACs, Cofactors and Subcellular Localization 
Compared to normal cells, the interplay between acetylation and deacetylation is 
dysregulated in almost all cancers. HDACs have been shown to be overexpressed or 
mutated in many cancers (Zhu et al., 2004; Ropero et al., 2006). Under normal conditions, 
HDACs associate with and regulate transcription factors, tumor suupressor genes and 
oncogenes. HDAC1 has been shown to be in a complex with Rb and to suppress the 
transcriptional activation of E2F (Brehm et al., 1998). Also SIRT1 has been shown to regulate 
the inflammatory, stress, and survival responses of p53 (Vaziri et al., 2001). Thus, it stands to 
reason that loss of HDAC1 or SIRT1 could result in uncontrollable growth of cell leading to 
transformation. In accord with this interpretation, SIRT1 has been shown to interact with 
DNMT1 to affect DNA methylation patterns (Espada et al., 2007). In acute myelogenous 
leukemia (AML), fusion of eight-twenty-one zinc-finger nuclear protein (ETO) to AML, a 
transcription activator, converts the AML protein into a dominant transcriptional repressor. 
The AML-ETO fusion protein permanently binds to HDAC corepressor complexes and/or 
blocks the recruitment of coactivator complexes leading to transformation (Scandura et al., 
2002). HDAC2 overexpression is a hallmark of familial-adenomatosis-polyposis-induced 
tumors (Zhu et al., 2004) and truncation of HDAC 2 is reported in sporadic tumors (Ropero 
et al., 2006). In addition, HDAC6 expression is correlated with better prognosis for breast 
cancer patients (Zhang et al., 2004), suggesting aberrant acetylation in breast tumors. In 
addition to aberrant levels of HDACs, several cancers also bear aberrant fusion proteins, 
mutations, or deletion of HATs and HAT releted genes (Bryan et al., 2002; Moore et al., 
2004). For example, in cancer cells there is global reduction in monoacetylation at H4K16 
(Fraga et al., 2005a), and HATs, such as p300 and CBP, are characterized as tumor 
suppressor genes since they can regulate the activity of oncoproteins, such as Jun, Fos, Myb 
and Rb (Yang et al., 2004). Likewise, p300 has been shown to be an interacting partner of the 
oncoprotein adenovirus E1A (Stein et al., 1999). CBP mutations have been shown to be 
involved in the initial steps of leukaemogenesis (Patrij et al., 1995). For the MYST family of 
HATs, mutations leading to loss of Tip60 acetyltransferase activity lead to apoptosis-
resistant phenotypes and rampant cell proliferation (Ikura et al., 2000). In AML, a chimera 
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protein is created by fusion of CPB to MOZ protein creating a protein with both p300/CBP 
and MYST domains (Yang et al., 2004; Borrow et al., 1996). The CBP-MOZ chimera protein 
exhibits gain-of-function characteristics leading to hyperacetylation and aberrant 
transcriptional activation. This leads to global inbalance of histone acetylation in cancer 
cells. Table 3 summarizes predicted impacts of acetylation and deacetylation in cancer. 
 
 
ALL: Acute Lymphoblastic Leukemia; AML: Acute Myeloid Leukemia; CRC: Colorectal cancer; MSI+: 
Colorectal cancer with microsatellite instability. 
Table 3. Aberrant Acetylation and Deacetylation Marks in Cancer 
2.3.2 Histone methylations 
Histone methylation occurs at either arginine or lysine residues in the tails of all histones. 
Two classes of enzymes catalyze the addition of methyl groups to histones: those that 
catalyse the addition of methyl group to arginine residues, called protein arginine 
methyltranferase (RHMT), and those that catalyze the addition of methyl groups to lysine 
residues, called histone lysine methyltransferase (HKMTs). S-adenosyl methionine (SAM) 
donates the methyl group in both cases of histone methylation (Pluemsampant et al., 2008). 
Histone methylation at arginine residues occurs at mono- or di-methylated states, while 
methylation at lysine residues occurs at mono-, di, and tri-methylated states. A total of 24 
arginine and lysine methylation sites has been identified in all the core histones so far.  
While DNA methylation generally represses transcription (except for gene body 
methylation), the functional impact of histone methylation is highly dependent on cellular 
context (Jenuwein and Allis, 2001). For example, histone methylation has been shown to 
cause both transcriptional activation and repression (Table 4). An emerging theme for these 
dual roles is explained by the fact that histone methylation creates motifs or domains that 
are recognized and bound by different proteins. The composition of these protein complexes 
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determines whether the modification results in gene activation or repression. Another 
explanation for this phenomenon is that histone modifier genes and regulatory genes have a 
tissue-specific expression pattern. The composition and recruitment of tissue specific 
proteins determines transcriptional states. Also, there is crosstalk between histone 
methylation and other epigenetic modifications. For example, several histone 
methyltransferases have been shown to direct DNA methylation (Tachibana et al., 2008; 
Zhao et al., 2009) by recruiting DNMTs. DNMT3L specifically interacts with H3 tails and 
induces recruitment of DNMT3a, however this interaction is strongly inhibited by H3K4me 
(Ooi et al., 2007). Thus, the transcription state of the chromatin is also an interplay between 
different epigenetic modifications. In addition, the domain composition of HMTs is a 
determining factor of the transcriptional state. Most HMTs contain a conserved SET (SUV39 
(Suppressor of variegation 3-9), Enhancer or zeste, Trithorax) domain which in combination 
with other domains/complexes has the ability to confer either transcriptional activation or 
repression. SET domain containing proteins are divided into five families: SET1, SET2, 
SUV39, RIZ (retinoblastoma protein interacting zinc-finger) and SMYD3 (SET and MYND-
domain containing protein 3) (Table 4). The mixed lineage leukemia (MLL), SMYD3, 
Nuclear receptor-binding SET domain protein-1 (NSD1) and CARM1 are HMTs that activate 
transcription. For example, MLL-specific methylation at H3K4 is followed by recruitment of 
bromo domain-containing trithorax complexes which result in formation of an open 
chromation (Milne et al., 2002). SMYD3 in complex with RNA polymerase II and HELZ, a 
helicase, is recruited to the promoters of target genes where it methylates H3K4 leading to  
 
 
Note that only a few of the HMTs are cited to illustrate their role as transcriptional activation or 
repression. 
Table 4. Histone Methylation at Specific Lysine and Arginine Residues 
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transcriptional activation. NSD1 methylation at H3K36 is responsible for activation of Hox 
genes (Wang et al., 2007). CARM1 methylation at H3R17 has also been shown to activate 
transcription by complexing with hormone receptor co-activator complexes (Hong et al., 
2004). On the other hand, SUV39H1, EZH2, RIZ1and PRMT5 participate in transcriptional 
repression. For example, EZH2 methylation at H3K27 leads to recruitment of chromo 
domain-containing polycomb complexes resulting in silencing of homeotic genes (Valk-
Lingbeek et al., 2004). SUV39h1 trimethylation at H3K9 of the promoters of cell cycle control 
genes leads to recruitment of chromo domain-containing heterochromatin protein 1 (HP1) 
which in turn leads to transcriptional repression (Bannister et al., 2001; Lachner et al., 2001). 
RIZ1 methylation at H3K9 of the promoters of cell cycle control genes leads to apoptosis in 
breast cancer cells (He et al., 1998). Finally, methylation at H2A/H3 by PRMT negatively 
regulates cyclin E transcription resulting in cell cycle arrest (Fabbrizia et al., 2002). Table 4 
summarizes the influence of histone methylation on transcription.  
As described for histone acetylation, histone methylation is also reversible. Two classes of 
enzymes are responsible for removing methyl groups from histones: lysine-specific 
methyltransferase (KMAT) and arginine-specific methyltransferase (RMAT). KMAT 
includes amine oxidase domain-containing demethylases (Forneris et al., 2005) and Jumonji 
C (JmjC) domain containing demethylases (Tsukada et al., 2006) while RMAT includes 
peptidylarginine deiminase 4 (PAD4) (Cuthbert et al., 2004; Wang et al., 2004). PAD4 is the 
only RMAT known so far and it does not convert methylarginine to arginine, instead it 
converts methylarginine to citrulline. Citrullination is described as yet a unique histone 
modification. Several KMAT exist and the first one discovered is the lysine-specific  
 
 
Table 5. Aberrant histone methylation and demethylation in cancer 
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demethylase-1 (LSD1). LSD1 is a typical H3K4 demethylase, but can change its substrate 
specificity when in complex with different accessory proteins. For example, LSD1 in 
complex with androgen receptor is able to demethylate H3K9 (Mwtzger et al., 2005). LSD1 is 
also able to synergistically work with HDACs and HATs to affect transcription of target 
genes. For example, over expression of LSD1 in HEK293 cells leads to decreased H3K4 
methylation which is in turn followed by H3 deacetylation and transcriptional repression 
(Lee et al., 2006). At the same time, inhibiting HDAC1 activity increases both H3 acetylation 
and H3K4 methylation (Lee et al., 2006).  
In cancer, there is aberrant expression and composition of histone-modifier and -regulator 
genes. For example, silencing of the nuclear receptor SET domain protein I (NSD1) results in 
decreased H3K36 and H4K20 methylation, which is believed to play a role in tumors of the 
nervous system (Berdasco et al., 2009). CpG Island hypermethylation by the histone 
methyltransferase ,RIZ1, has been described in many cancers (Du et al., 2001). Suppressor of 
the zest 12 homolog (SUZ12) which is a component of the PCR2/EED/EZH2 complex that 
methylates H3K9 and H3K27 is involved in cell proliferation and survival in tumors (Li et al., 
2007). In leukemias, the presence of mixed lineage leukemia (MLL) fusion oncoproteins leads 
to aberrant patterns of H3K79 and H3K4 methylation and altered gene expression in these 
tumors (Krivtsov et al., 2008; Wang et al., 2009). Some histone demethylases have also been 
found to be overexpressed in prostate cancer and squamous carcinomas (Shi et al., 2007). For 
example, LSD1 overexpression is a predictive biomarker for prostate cancer (Kahl et al., 2006) 
2.3.3 Histone phosphorylation 
Histone phosphorylation is described as the addition of a phosphate group (PO3-) to histone. 
So far, a small number of kinases has been shown to phosphorylate histones, and these 
include protein kinase B (PKB/AKT), ribosomal S6 kinase-2 (Rsk-2), mitogen- and stress-
activated protein kinases 1 and 2 (Msk1/2), mixed lineage triple kinase-alpha (MLTK-┙), 
and aurora kinases. The most interesting of the histone kinases are the aurora kinases. In 
normal cells, aurora kinases are involved in chromosomal segregation, condensation and 
orientation (Katayama et al., 2003). For example, aurora-phosphorylates both H3S10 and 
H3S28 during mitosis and meiosis (Andrews et al., 2003). Aurora kinases are 
serine/threonine kinases that include auroras A, B and C. These proteins share similar 
carboxyl terminal catalytic domains, but divergent amino terminals of variable length. In 
cancer cells, aurora kinases are frequently overexpressed and their overexpression is 
implicated in oncogenic transformation, as evidenced by chromosomal instability and 
derangement of multiple tumor suppressor and oncoprotein-regulated pathways. The 
mechanism through which these kinases are activated is dependent on the 
microenvironment of the cell. These mechanisms include, but are not limited to, activation 
by mitogens, cytokines, stress, signaling pathways (e.g. Ras-mitogen-activated protein 
kinase pathway (MAPK)) and chemical and environmental toxicants.  
Functionally, histone phosphorylation alone, or when synergistically-coupled to other 
histone modifications (e.g. acetylation and methylation), can either facilitate or repress 
transcription (Cheung et al., 2000). This dichotomy is explained by the fact that histone 
phosphorylation can create domains that are recognized and bound by transacting factors, 
the composition of which determines the transcriptional state. Also histone phosphorylation 
can facilitate or repress further acetylation or methylation thereby regulating the 
transcriptional state of chromatin. For example, phosphorylation at  threonine 11 has been 
shown to hasten removal of repressive H3K9 methylation by recruitment of the histone 
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demethylase Jumonji C domain containing protein (JMJD2C) (Metzger et al., 2008). At this 
capacity, phosphorylation facilitates transcription by recruitment of histone demethylases. 
In addition, phosphorylation at H3 serine 10 inhibits recruitment of heterochromatin protein 
1 (HP1) (Fischle et al., 2005; Hirota et al., 2005), which in turn prevents recruitment of 
DNMTs (DNMT1 and DNMT3a) thereby leaving chromatin in the open conformation and 
ready for transcription. At this level, phosphorylation prevents methylation of DNA by 
preventing recruitment of DNMTs. Phosphorylation can also facilitate transcription by 
allowing recruitment of histone acetyltransferase (HAT). For example, mutation at H3 serine 
10 ablates recruitment of HATs (Chuang et al., 2000; Lo et al., 2000). Phosphorylation can 
also activate genes which in turn activate signaling pathways responsible for gene 
activation. Stimulation of inflammatory cytokine signaling activates IkB kinase ┙ which 
phosphorylates histone H3 at serine 10 in the promoters of multiple nuclear factor 
responsive genes (Anest et al., 2003; Yamamoto et al., 2003). These phosphorylations result 
in expression of several inflammatory responsive genes. Lastly, it is been shown that 
phosphorylation of core H3 at serine 10 (cH3S10) and threonine 11 (cHT11) occur during 
active transcription (Chuang et al., 2000; Nowak and Cores, 2000, 2004, Metzger et al., 2008), 
suggesting that the negative phosphate groups added to histones might neutralize the 
positive charges on DNA, thus causing chromatin to unwind and allow transcription to 
continue. Conversely, evidence for transcriptional repression due to histone 
phosphorylation is mounting. For example, during mitosis, H3S10 phosphorylation is 
associated with condensed chromosome (Goto et al., 1999). Aurora-B kinase-mediated 
phosphorylation of H3S28 is also associated with condensed chromosome. Constitutive 
phosphorylation of H1 through the Ras-MAPK pathway leads to chromatin condensation 
(Chadee et al., 1995). In addition, mammalian Sterile20-like 1 (Mst1) phosphorylation of 
H2B-14 is associated with condensed chromatin leading to apoptosis (Cheung et al., 2003). 
 
 
Table 6. Aberrant Histone Phosphorylation in Cancer 
Like other histone modifications, histone phosphorylation is counteracted by 
dephosphorylation. Phosphatases catalyze the removal of phosphate groups from histones. 
For example, phosphatase type 1 (PP1) interacts with aurora-B during mitosis as a feedback 
mechanism (Katayama et al., 2001). Also PP1 regulates Aurora-B and H3 phosphorylations 
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during cells division (Murnion et al., 2001). In cancer cells, the balance between 
phosphorylation and dephosphorylation is dysregulated. For example, histone 
phosphorylation has been shown to play a role in cancer through modulation of the DNA 
repair response, chromosome instability and apoptosis. Recently JAK2, a nonreceptor 
tyrosine kinase, has been shown to be activated by chromosomal translocation and point 
mutations in hematological malignancies (Dawson et al., 2009). Also, JAK2 has been shown 
to phosphorylate H3Y41 which prevents the recruitment of heterochromatin protein 1┙ 
(HP1┙) leading to increased expression of genes in this region. Phosphorylation at serine 139 
in the highly conserved C-terminal tail (–SQEY) of H2A.X has been shown to play an 
important role in DNA double-strand break (DSB) repair and tumor suppression 
(Fernandez-Capetillo, O. et al. 2004). In addition, H3S10 and H2BS14 phosphorylations play 
a role in chromosomal instability and apoptosis resistance, respectively which are both 
hallmarks  of cancer (Fischle, W. et al. 2005; Hirota, T. et al. 2005; Hanahan and Weinberg, 
2000; Ahn, S.H. et., 2005).Activation of MAPK pathway by environment carcinogens leads to  
phosphorylation of H3 which in turn results in the induction of immediate early genes. 
More specifically, ultraviolet light has been shown to activate MAPK pathways resulting in 
phosphorylation of H3S10 by p38 kinase.  
2.3.4 Histone ubiquitination and sumoylation 
Ubiquitination and sumoylation involve the transfer of a polypeptide to the histone tail. The 
polypeptide molecules for ubiquitination and sumoylation are ubiquitin and small ubiquitin 
related modifier (SUMO) (Takada et al., 2007), respectively. The enzymatic cascade 
responsible for ubiquitination and sumoylation are similar, with three classes of enzymes 
involved in both instances: E1 activating enzymes, E2 conjugating enzymes and E3 ligating 
enzymes. In the first step of this multistep cascade, E1 adds Ubiquitin/SOMO to the target 
substrate in an ATP dependent manner. E2 then transfers the Ubiquitin/SOMU to E3 which 
associates and ligates the Ubiquitin/SOMU to histones (Nathan et al., 2003). Histone 
ubiquitination involves mono-ubiqutination which is different from poly-ubiquitination in 
that it does not result in proteosomal degradation of the target histone. Depending on the 
lysines that are ubiquitinated, ubiquitination can result in transcriptional activation or 
repression (Table 7). For example, both H2A and H2B are targets of mono-ubiquitination, 
and mono-ubiquitination has been shown to be a precursor to histone methylation (Gerber 
and Shilatified, 2003; Hampsey and Reinberg, 2003; Osley, 2004; Margueron et al., 2005). In 
particular, mono-ubiquitination at H2B lysine 120 (H2BK120) by E3 ligase (RNF20/RNF40) 
initiates methylation at H3 lysine 4 (H3K4) resulting in recruitment of homeobox genes (Zhu 
et al., 2005) and transcriptional activation. Conversely mono-ubiquitination at H3 lysine 119 
(H3K119) by Bmi/Ring1A induces transcriptional repression (Wand et al., 2004). 
It is not completely clear what role sumoylation plays on transcriptional regulation, 
however sumoylation has recently been shown to cause transcriptional repression (Shiio 
and Eisnman, 2003; Girdwood et al., 2003) (Table 1). For example, H4 sumoylation is 
associated with recruitment of HP1 and HDAC which is known to repress transcription. A 
number of oncogenes and tumor suppressor genes, including PML, Mdm2, c-Myb, c-Jun, Rb 
and p53, undergo SUMOylation (Muller et al., 1998; Bushmann et al., 2000; Bies et al., 2002; 
Schmidt et al., 2002; Huang et al., 2004; Besten et al., 2005; Ghioni et al., 2005; Ghost et al., 
2005). SUMOylation of Mdm2 increases its E3 activity toward p53 tumor suppressor. SUMO 
negatively regulates c-Jun activity and thus restricts its oncogenic capacity. SUMOylation of  
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Red arrows indicate transcriptional activation, while black arrows indicate transcriptional repression. 
Table 7. Summary, Impact of Posttranslational Modification of Histones on Transcription 
c-Myb increases its stability, but negatively regulates its transactivation function of. 
Increasing evidence supports the notion that protein SUMOylation is important during the 
course of tumorigenesis and oncogenesis, and altered in human cancers, however further 
work is needed to determine the impact of sumoylation on cancer.  
In summary, epigenetic modifications are not stand alone processes. Instead, considerable 
crosstalk exists among the different types of epigenetic marks. In accord with this principle, 
epigenetic marks by themselves, or synergistically with other epigenetic marks, function to 
either repress or activate transcription (Table 7). Of relevance to epigenomic regulation is 
that all epigenetic modifications identified to date have been shown to be reversible. Genes 
regulated by epigenetic modification remain intact and can therefore be returned to their 
original state. The reversibility of epigenetic mechanisms makes them highly susceptible to 
pharmacological intervention and therefore, ideal targets for cancer therapeutics.  
3. Epigenetic therapies 
Genetic mutations and gross structural defects permanently activate or inactivate genes; 
however genes modified by aberrant epigenetic modification remain structurally intact and 
subject to reversal of aberrant epigenetic modifications that can restore their original state. 
This phenomenon has made epigenetic modifications an ideal target for the treatment of 
many diseases, including cancer. As discussed in previous sections, cancers are plague with 
aberrant epigenetic modifications which have been shown to contribute to initiation and 
transformation. In fact, several exogenous chemicals used to treat cancers have been shown 
to cause unintended epigenetic modifications which in many cases have led to exacerbation 
of tumor progression. These factors, combined and our understanding of epigenetic 
modifying enzymes, pathways and accessory proteins pivotal to epigenetic modifications, 
have lead to the development of therapies targeting DNA methylation and DNMTs, histone 
modifications and histone modifying enzymes (i.e HAT, HDAC, kinases, HMT, SUMO 
ligase, ubiquitin ligase, etc.). Indeed, therapies targeting chromatin remodeling complexes 
have attracted significant interest in recent years as a means for cancer prevention, either 
alone or in combination with conventional cancer treatments.  
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3.1 DNA Methyltransferase inhibitors (DNMTis) 
Inhibitors of DNA methylation (DNMTis) cause reactivation of silenced genes, inhibition of 
cell proliferation, apoptosis and enhancement of sensitivity to other cancer drugs. DNMTis 
can be grouped into nucleoside DNMTis and non-nucleoside DNMTis, based on their 
structure and mode of action. Nucleoside DNMTi are analogues or derivatives of the 
nucleoside cytidine and they include 5-azacytidine (5-Aza-CR), 5-Aza-2-deoxycytidine (5-
Aza-CdR), zebularine, cytarabine and 5-Fluoro-2-deoxycytidine. The cytidine analogues (5-
Aza-CR and 5-Aza-CdR) have been approved by FDA for the treatment of myeloid 
malignancies in the USA. The anticancer activity of these drugs is believed to be mediated 
by two mechanisms: (1) cytotoxicity which stems from incorporation of these drugs into 
DNA and/or RNA, and (2) reactivation of tumor suppressor genes by demethylation of 
their promoter regions (Jones and Liang, 2009). These drugs do not demethylate DNA per 
se, but rather with continued replication, cytidines are replaced by the cytidine analogues 
resulting in serial dilution of methylable cytidines. In addition, DNMTs are trapped in 
covalent adducts with DNA through the incorporated cytidine analogues. 5-Aza-CR and 5-
Aza-CdR are taken into the cell through the concentrated nucleoside transporter 1 (hCNT1) 
(Rius et al., 2009). Once inside the cell, 5-Aza-CR is phosphorylated by uridine-cytidine and 
5-Aza-CdR by diphosphate kinase (Stresemann et al., 2008; Issa et al., 2009) which in turn 
convert them into active triphosphates (i.e. 5-Aza-CTP and 5-Aza-dCTP). 5-Aza-CTP is 
incorporated into the DNA resulting in the formation of covalent adducts between DNMTs 
and DNA (Santi et al., 1984). This traps the DNMTs and prevents further methylation. In 
other studies, 5-Aza-dCTP was shown to be incorporated into RNA which interferes with 
ribosomal biogenesis and protein synthesis (Momparlar et al., 1984; Stresemann et al., 2008). 
In accord with these findings, Ghoshal et al. 2005 and Kuo et al. 2007 have both shown that 
5-Aza-CTP and 5-Aza-dCTP hypomethylate the genome through passive dilution of 
cytidine and not through active demethylation. Because of the cytotoxicity and instability of 
5-Aza-CR and 5-Aza-CdR, DNMTis cannot be continually given to patients. For this reason, 
zebularine has been developed as an alternative. Although this drug works in a manner 
similar to 5-Aza-CR and 5-Aza-CdR, it is more stable and less toxic than 5-Aza-CR and 5-
Aza-CdR DNMTis (Zhou et al., 2002; Cheng et al., 2003). In line with these findings, 
zebularine has been shown to reactivate tumor suppressor genes (Flotho et al., 2009; Billam 
et al., 2010), enhance tumor cells’ chemotherapy and radiation sensitivity (Dote et al., 2005), 
exert angiostatic and antimitogenic activities (Balch et al., 2005; Hellebrekers et al., 2006) and 
to be stable enough for oral administration (Zhou et al., 2002; Cheng et al., 2003). In 
addition, at low doses, zebularine can be given to patients continuously without the overt 
cytoxicity associated with 5-Aza-CR and 5-Aza-CdR. Another cytidine analogue, 5-fluoro-2-
deoxycytidine (FdCyd) has been shown to cause demethylation in human breast and lung 
cancer cells (Beumer et al., 2008). In the case of FdCyd, the hydrogen atom at carbon-5 (C5) 
which is the methyl acceptor during the methylation reaction is replaced by a fluorine atom. 
When FdCyd is incorporated into DNA, the ┚-elimination step in which DNMT transfers the 
methyl group to the cytidine is inhibited. At the same time, the fluorine atom traps the 
DNMT to prevent elimination of the FdCyd moiety (Jones et al., 1980; Reither et al., 2003). 
FdCyd is currently in Phase I clinical trials for the treatment of breast and other solid tumors 
(Gowher et al., 2004) (Table 8). Moreover, FdCyd, in combination with other epigenetic 
drugs (i.e. tetrahydrouridine and dihydro-5-azacytidine (DHAC), is being evaluated in 
clinical studies for the treatment of malignant mesothelioma (Kratzke et al., 2008). 
Although nucleoside DNMTis have proven effective for the treatment of cancers, their 
cytotoxicity remains a significant limitation. To address this shortcoming, non-nucleoside 
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DNMTis are being evaluated. Non-nucleoside DNMTis include procaine, L-trytophan 
derivatives, RG108, hydralazine, MG98, procainamide, and epigallocatechin-3-gallate (EGCG).  
Procaine is a local anesthetic drug that can also function as a DNMTi. For example, procaine 
has been shown to cause global demethylation and reactivation of tumor suppressor genes 
in human breast cancer cells (Jin et al., 2009). Unlike the nucleoside analogues, procaine 
competes with DNMTs for binding to CpG rich regions (Jin et al., 2001). Procainamide and 
hydralazine are antiarrhythmic drugs that can also function as DNMTis, and both agents 
have been shown to inhibit DNA methylation through interactions between the nitrogen 
atom of procainamide and hydralazine with the lys-162 and Arg-240 moities in the catalytic 
site of DNMTs (Song et al., 2009; Singh et al., 2009; Mund et al., 2006). In accord with these 
findings, procainamide has been shown to specifically inhibit DNMT1 (Lee et al., 2005). 
RG108 is a small molecule inhibitor of DNMTs that inhibits free DNMTs (Brueckner et al., 
2005). This drug works by blocking the catalytic pocket of DNMTS without the formation of 
covalent adducts that cause cytoxicity (Stressmann et al., 2006). Studies have also shown 
RG108 to cause demethylation and reactivation of tumor suppressor genes without affecting 
the methylation level of microsatellite regions in lung cancer cells (Suzuki et al., 2010), 
suggesting a specificity level in RG108 that has not been seen in other DNMTis. Table 8  
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AML: Acute Myeloid Leukemia; CR: Complete Remission; HI: Hematologic Improvement; MDS: 
Myelodysplastic Syndrome; PR: Partial response; ORR: Overall Response Rate; CR: Conventional Care 
Regimens; N/A: Data not available; SD: Stable Disease. Note that only few DNMTis are shown here to 
illustrate their role in the treatment of cancers. 
Table 8. DNMTis and Their Impact in Cancer  
summarizes the DNMTis in clinical trial and their efficacy for cancer treatment either alone 
or in combination with other regimens.  
3.2 Histone acetyltransferase inhibitors (HATis) 
HAT inhibitors can be classified into synthetic peptide CoA base bisubstrate HATis, natural 
product HATis and small molecule HATis (Table 9). The synthetic bisubstrate HATis were 
the first to be identified based on the observation that polyamine-CoA conjugates can inhibit 
HAT activity in cell extracts (Cullis et al., 1982). In particular, H3-CoA-20 and Lys-CoA 
specifically inhibit pCAF and p300 (Lau et al., 2000) rather weakly. Introduction of a phenyl 
or methyl group between lysine and CoA improves the inhibition fourfold (Sagar et al., 
2004). Most of the synthetic bisubstrate HATis work by mimicking the acetyl CoA-lysine 
intermediate complex in the HAT reactions. Crystal structure information between GCN5 
and these HATis shows that GCN5 interacts with the pyrophosphate moity, the pantothanic 
moiety and the phosphate group of CoA. The major deficiency for this class of HATis is 
their impermeability to cells. Unfortunately, most of the naturally occurring HATis also 
suffer from a similar problem. For example, anacardic acid isolated from the shell of 
cashewnuts displays permeability restriction in vitro. Nevertheless, garcinol and isogarcinol 
were both shown to inhibit p300 and pCAF (Balasubramnyam et al., 2004; Mantelingu et al., 
2007). The derivative of isogarcinol, LTK14, was shown to selectively inhibit p300, but not  
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Table 9. HAT Inhibitors and Their Selectivity 
pCAF (Mantelingu et al., 2007). The best characterized of the naturally occurring HATis is 
Curcumin, which is isolated from the Curcuma longa rhizome. Curcumin has shown high 
efficacy in the prevention and treatment of colorectal, prostate, kidney, lung, ovarian, breast, 
cervical and liver cancers (Balasubramnyam et al., 2004). The last group of HATis includes a 
number of small molecules designed to overcome the challenges in permeability of the first 
two groups. These include ┛-butyrolactone MB-3, quinoline and isothiazolone and their 
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derivatives. Although in their infancy, isothiazolone has been shown to inhibit the 
enzymatic activity of both pCAF and p300 leading to reduction in cell proliferation of 
human ovarian and colon cancer cell lines (Stimson et al., 2005). ┛-butyrolactone MB-3 
inhibits GCN5 and contains an ┙┚-unsaturated carbonyl group that is prone to covalently 
bind to the thiol group in the active site of GCN5 (Biel et al., 2004). 
3.3 Histone deacetylase inhibitors (HDACis) 
HDAC inhibitors (HDACis) have been classified into seven categories based on their 
chemical structures and mode of inhibition: short chain fatty acids, benzamides, cyclic 
peptides, electrophilic ketones, hydroxamine-acid-derived compounds (Espino et al., 2005; 
Rasheed et al., 2007), miscellaneous compounds (e.g. Depudecin and MGCD-0103) and 
sirtuin inhibitors (Table 10). Sirtuin or class III HDACis can be further classified structurally, 
but for simplicity, they are classified here into a single group. For details on class III HDACi 
subgroups, the reader is referred to Schemies et al., 2009. Class I, II and IV HDACis share a 
common metal binding domain that serves to block Zn+ chelation at the active site (Miller et 
al., 2003). Because of the presence of a different co-factor (nicotinamide (NAD)) at the active 
site of class III HDACs, zinc-dependent HDACis are ineffective against them. Class III   
 
 
Table 10. Histone Deacetylase Inhibitor Subgroups 
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HDACis are inhibited by nicotinamide, NAD+ analogues, indoles, hydroxynaphthaldehyde 
derivatives, Splitomicins, Suramins and kinase inhibitors (Schemies et al., 2009). NAD works 
by specifically blocking the entry of nicotinamide adenine dinucleotide into the active site of 
class III HDACs. The modes of action of other satiun inhibitors are still unknown. While 
zinc-dependent HDACis are established anticancer drugs, and two inhibitors (Vorinostat 
(SAHA), Romidepsin) have been approved for cancer treatment in the United States 
(Johnstone et al., 2002), much less is known about the biological consequences of sirtiun 
inhibitors (North et al., 2004; Wesphal et al., 2007; Fatkins et al., 2008). In fact, sirtuin 
inhibitors shown to be effective in lower organisms, do not work on human subtypes (Biel et 
al., 2005; Schafer et al., 2005). In general, HDACis have shown to induce cell cycle arrest and 
apoptosis in G1 or G2/M. For example, in response to HDACis, p21 gene is consistently 
upregulated in a p53-independent manner and p21 expression is correlated with cell cycle 
G1 arrest (Gui et al., 2004; Vrana et al., 1999). The upregulation of p21 gene is correlated 
with increased acetylation of histones H3 and H4 near the p21 promoter (Hirsch et al., 2004). 
In addition, HDACis, such as butyrate and trichostatin A, have been shown to stabilize p21 
mRNA (Hirsch et al., 2004). Moreover, HDAC inhibition represses cyclins A and D, and 
activates p16 and p27 to induce cell cycle arrest (Sandor et al., 2000; Wharton et al., 2000). In 
other studies, HDACis upregulate the expression of pro-apoptotic genes (i.e., TRAIL, DR5, 
Bax, Apaf-1, Bmf, Bim and TP2) and/or downregulate the expression of anti-apoptotic 
genes (i.e., Bcl-2, Mcl1, and XIAP) (see review by Bolden et al., 2006). The biggest advantage 
for many HDACis is that they can induce their effect in the nano/micromolar range, as seen 
for SAHA and butyric acid, respectively (Espino et al., 2005; Kelly et al., 2003). Moreover,  
 
 
HDAC: Histone deacetylase; SAHA: Suberoylanilide hydroxamic acid; SIRT: Sirtuin; TSA: Trichostatin 
A; VPA: Valproic acid. 
Table 11. HDAC Classes and Relevant Inhibitors 
www.intechopen.com
 Current Cancer Treatment – Novel Beyond Conventional Approaches 
 
566 
HDACis have been shown to suppress angiogenesis and to activate and enhance the host 
immune system in cancer patients (Bhalla et al., 2005; Dokmanovic et al., 2005; Bolden et al., 
2006). 
At the clinical level, HDACis function synergistically with a host of structurally and 
functionally diverse cancer drugs, chemotherapeutic agents and biologically active 
polypeptides. In this manner, HDACis can increase the efficacy of other drugs by increasing 
target susceptibility. For example, in breast cancer therapy, the effectiveness of 
topoisomerase II inhibitors can be increased by pretreatment with SAHA (Marchion et al., 
2004). In addition, HDACis have been used in combination with DNA demethylating agents 
in an attempt to reactivate silenced genes involved in tumor suppression. For example, three 
Phase I/II trials combining 5-Aza-CR or decitabine with HDAC inhibitors (phenyl butyrate 
or valproic acid) in patients with AML and MDS showed both tolerability and promising 
efficacy (Gore et al., 2006; Maslak et al., 2006; Garcia-Manero et al., 2006). Of a total of 93 
patients who were treated, 14 showed complete remissions (CR), two showed partial 
complete remission (pCR), four showed partial response (PRs) and 6 showed hematologic 
improvements (HI) (Table 12). These studies combined have an overall response rate of 28%. 
In another phase I clinical study, the efficacy of CI-994 and various chemotherapeutic agents 
was examined in 104 patients. The results from these studies showed that CI-994 at doses of 
4-10mg/m2/day can be safely administered to patients for 7-21 days in a 3-4 week dosing 
regimen (Nemunaitis et al., 2003; Undevia et al., 2004; Paur et al., 2004). In this study, two 
patients with esophageal and bladder cancer showed complete remission (CR) and five 
(three with non- small lung cancer and two with colorectal cancer) demonstrated partial 
remission (PR). On a related note, some leukemia and breast cancers plagued with the 
expression of fusion proteins (RAR–PML, RAR–PLZF or AML–ETO chimeras) that inhibit 
differentiation have shown improvements when HDACis in combination therapy with 
transretinoic acid (ATRA) is used to inhibit the function of these fusion proteins (Johnstone 
et al., 2003) (Table 12). Another emerging area of combination therapy is the use of HDACis 
with tyrosine kinase inhibitors in cancers that overexpress antiapoptic genes. For example, 
SAHA, LBH-589, LAQ-824 and romidepsin have demonstrated synergistic apoptotic activity 
in combination with imatinib and other tyrosine kinase inhibitors, such as AMN-107 in 
imatinib-sensitive, as well as imatinib-resistant bcr-abl leukemic cells (Nimmanapalli et al., 
2003a, 2003b; Yu et al., 2003;  Kawano et al., 2004; Fiskus et al., 2006). 
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5-AZA: 5-Azacytidine; AML: Acute myeloid leukemia; APML: ATRA: All-trans-retinoic acid; CR: 
Complete response; CRi:  Morphologic complete remission with incomplete count recovery; CRp: 
Complete response without complete platelet recovery; HDACi: Histone deacetylase inhibitors; MDS: 
Myelodysplastic syndrome; PR: Partial response; SAHA: Suberoylanilide hydroxamic acid; SD: Stable 
disease. 
Table 12. HDACis in Clinical Trial and Combination Therapies 
4. Concluding remarks 
Only a handful of studies have been published examining the usefulness of drugs targeting 
ubiquitination, sumolyation and phosphorylation of histone as a means to combat the 
proliferative and differentiation deficits seen in cancer. The above discussion was not 
intended to provide complete coverage to a fast emerging field at rather as a means to 
highlight the most promising therapies investigated to date employing epigenetic-based 
approaches. Although these early successes establish the promise of epigenetic-based 
chemotherapeutic regimens in the treatment of various cancers, the degree to which gene-
specific epigenetic modifications can be achieved, or the extent to which targeted therapies 
can be developed using epigenetic approaches remains to be fully investigated.  
Undeniably, the ultimate benefit to be realized from such strategies is based on the fact that 
the epigenetic modifications in cancer cells are reversible and subject to environmental 
control. Clearly, the jury is still out!  
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